Pacific Biosciences of California

Pacific Biosciences of California Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 20% discount to our quantitative fair value estimate of $3.41 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 4.9 falls in the top 20% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -4.2%, for example, falls in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the company's weak financial health rating could portend bankruptcy risk if economic conditions weaken.